Research
Hormonal
Semaglutide (2.4 mg/week) achieves high rates of NASH resolution without worsening fibrosis in patients with obesity.
Semaglutide (Ozempic/Wegovy) is a highly effective treatment for resolving NASH. In trials, 59% of patients achieved resolution of the disease without worsening liver scarring, compared to only 17% on placebo. It is administered as a weekly injection.
GoodSupportsHIGH confidence
subcutaneous administration of semaglutide at a dose of 0.4 mg/day was associated with resolution of NASH without worsening of fibrosis in 59% of patients compared with 17% in the placebo group (p <0.001) [62].
Why this rating
Based on a Phase 2 RCT cited in the review; Phase 3 data is mentioned for weight loss but NASH resolution data is from Phase 2.
Source
Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment
С. Г. Канорский · South Russian Journal of Therapeutic Practice · 2021
DOI 10.21886/2712-8156-2021-2-3-18-29
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →